Actavis Dooms Exforge Buyers' Pay-For-Delay Claims
Buyers of the hypertension medication Exforge will have to pursue their pay-for-delay allegations against the drug's brand maker Novartis and generics company Par Pharmaceutical under a harder-to-prove legal standard, thanks to...To view the full article, register now.
Already a subscriber? Click here to view full article